Producing engineered extracellular vesicles for therapeutics applications: in this study, Kristin Luther, Joe Nabhan at Vesigen Therapeutics, Inc. and collaborators evaluated two scalable strategies for generating GFP-loaded ARMM-engineered EVs: transient transfection and stable cell line-based production. The upstream ARMM production processes used a suspension HEK293-derived line called 5B8 from Lonza, with production assessed in both shake flasks and bioreactors. For downstream ARMM purification, they employed Tangential Flow Filtration and Anion Exchange Chromatography
https://lnkd.in/eWs8TfSM
In vivo, ARMMs demonstrated rapid biodistribution, primarily to the spleen and liver, with lesser distribution to the kidneys and lungs. The successful scale-up of ARMM production highlights the potential of engineered EVs. An article also authored by Ali Navaei, Leah Gens, Carson Semple, Pearl Moharil, Ilaria Passalacqua, Komal Vyas, Qiyu Wang, Shu-Lin Liu, Lucy Sun, Senthil Ramaswamy and Davide Zocco #extracellularvesicles #exosomes #bioengineering #translationalmedicine #cellculture #Vesiculab
Global Corporate Development, M&A, Strategy, and Ventures Leader
4moCongratulations on the index inclusion - great to see.